Form 4: Catalyst Pharma CEO Exercises Options, Sells Shares

Catalyst Pharmaceuticals CEO Richard J. Daly exercised 50,000 stock options and subsequently sold 22,970 shares to cover the exercise price and tax obligations.

Summary

• Richard J. Daly, President and CEO of Catalyst Pharmaceuticals, Inc. (CPRX), exercised 50,000 options to purchase common stock at an exercise price of $2.24 per share.
• Concurrently, Mr. Daly sold 22,970 shares of common stock on the open market at a price of $20.62 per share.
• The sale of shares was explicitly stated to fund the exercise price of the options and cover tax withholding obligations.
• Following these transactions, Mr. Daly directly owns 226,794 shares of common stock and 2,184,753 options to purchase common stock.
• The transactions occurred on August 26, 2025.
• The options vested in three annual tranches beginning December 19, 2019, and have an expiration date of December 19, 2025.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The exercise of options by the CEO is a positive signal of confidence, but the subsequent sale, even for tax purposes, introduces a slight neutral element. The transaction is routine and pre-planned, mitigating strong positive or negative sentiment.

Positives

• The exercise of 50,000 stock options by the CEO indicates a degree of confidence in the company's future, as he is converting potential value into actual shares.
• The exercise price of $2.24 is significantly lower than the market sale price of $20.62, demonstrating a substantial unrealized gain on the options.
• The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-planned and automated transaction, which reduces concerns about opportunistic insider trading.

Negatives

• The sale of 22,970 shares by the CEO, even if for tax and exercise cost purposes, represents a reduction in his direct equity holdings.
• While explained, any insider selling can sometimes be perceived negatively by the market, as it reduces the insider's direct exposure to the company's stock performance.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is solely an insider transaction report.

Management Comments

• Shares were sold on the open market to fund the exercise price and tax withholding due from Mr. Daly on the exercise of the 50,000 stock options.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information relevant to broader industry trends or competitive analysis. It reflects an individual executive's equity management rather than a corporate strategic move.

Stakeholder Impact

• Shareholders may view the exercise of options as a positive sign of management's belief in the company's value, while the sale of shares for tax purposes is a common and generally accepted practice for executives.
• Employees are not directly impacted by this routine insider transaction.
• Customers, suppliers, and creditors are not directly impacted by this routine insider transaction.

Key Dates

Recommendation

This Form 4 details a routine, pre-planned insider transaction where the CEO exercised stock options and sold a portion of the acquired shares to cover the exercise cost and tax obligations. While the exercise of options can be seen as a positive signal of confidence, the subsequent sale is a common practice and does not indicate a lack of belief in the company's future. The transaction volume is not significant enough to warrant a strong buy or sell recommendation based solely on this filing. Investors should consider broader company fundamentals and market conditions.

Keywords

Catalyst Pharmaceuticals, CPRX, Richard J. Daly, Insider Trading, Form 4, Stock Options, CEO, Equity Transaction, Rule 10b5-1